Deutsche Bank AG Boosts Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Deutsche Bank AG lifted its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 6.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 402,874 shares of the company's stock after purchasing an additional 23,327 shares during the quarter. Deutsche Bank AG owned about 0.51% of Viridian Therapeutics worth $7,723,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. FMR LLC grew its position in Viridian Therapeutics by 6.2% during the 4th quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after purchasing an additional 698,434 shares during the last quarter. Vanguard Group Inc. grew its position in Viridian Therapeutics by 4.0% during the 4th quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock valued at $88,087,000 after purchasing an additional 174,952 shares during the last quarter. Deep Track Capital LP grew its position in Viridian Therapeutics by 20.6% during the 4th quarter. Deep Track Capital LP now owns 4,522,741 shares of the company's stock valued at $86,701,000 after purchasing an additional 771,796 shares during the last quarter. Alliancebernstein L.P. raised its holdings in Viridian Therapeutics by 3.8% in the 4th quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after acquiring an additional 84,255 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its holdings in Viridian Therapeutics by 38.6% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 1,670,000 shares of the company's stock worth $32,014,000 after acquiring an additional 465,000 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on VRDN. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. Royal Bank of Canada decreased their price target on Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating for the company in a research note on Wednesday, May 7th. JMP Securities decreased their price target on Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $36.00 price target on shares of Viridian Therapeutics in a report on Tuesday. Finally, The Goldman Sachs Group dropped their price target on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, Viridian Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $36.70.

Viridian Therapeutics Stock Performance

Viridian Therapeutics stock traded down $0.10 during mid-day trading on Friday, reaching $13.57. 645,430 shares of the stock traded hands, compared to its average volume of 1,191,100. The stock has a market capitalization of $1.11 billion, a PE ratio of -3.15 and a beta of 0.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. Viridian Therapeutics, Inc. has a 12-month low of $9.90 and a 12-month high of $27.20. The business's 50-day moving average is $13.17 and its 200-day moving average is $16.86.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, beating analysts' consensus estimates of ($0.95) by $0.08. The company had revenue of $0.07 million during the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The business's revenue for the quarter was up .0% on a year-over-year basis. As a group, sell-side analysts predict that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.